Street Missing 'Eye-Catching' CymaBay Data, Says Piper Sandler
August 03, 2020 at 14:36 PM EDT
August 3's topline data from CymaBay's halted Phase 3 study answered key questions for seladelpar around its effect on itch, a hallmark symptom of primary biliary cholangitis, Piper Sandler analyst Yasmeen Rahimi tells investors in a research note.
